Welcome to our dedicated page for Silence Therapeutics Plc news (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics Plc stock.
Silence Therapeutics plc (Nasdaq: SLN) generates a steady flow of news as a global clinical-stage biotechnology company developing siRNA (short interfering RNA) therapies. Its updates focus on the progress of programs built on its proprietary mRNAi GOLD™ platform, which is designed to create precision engineered siRNAs that target and silence disease-associated genes in the liver.
Investors following SLN news can expect detailed coverage of clinical trial milestones, particularly for divesiran, the company’s first-in-class siRNA candidate for polycythemia vera (PV). Recent announcements describe additional Phase 1 data presented at major hematology meetings, durable hematocrit control and reduced need for phlebotomies in PV patients, and the completion of enrollment in the global, randomized SANRECO Phase 2 study.
Silence also issues news on its broader pipeline and strategy, including updates on zerlasiran for cardiovascular disease, extra-hepatic siRNA targeting work, and its collaboration program SLN312 licensed to AstraZeneca. Financial result press releases provide context on research and development spending, cash and investment balances, and the company’s stated cash runway expectations, alongside commentary on operational priorities.
Corporate governance and leadership developments feature in SLN news as well, such as changes to the Board of Directors, executive transitions and outcomes of shareholder votes at the annual general meeting. Conference participation announcements highlight company presentations at healthcare and investor events, where management discusses the siRNA platform, clinical data and pipeline priorities.
By monitoring this news page, readers can review a chronological record of Silence Therapeutics’ clinical, financial and corporate disclosures related to SLN, with an emphasis on the evolution of its siRNA programs in cardiovascular disease, hematology and rare diseases.
Silence Therapeutics (NASDAQ: SLN) announced leadership changes effective December 14, 2025. Craig Tooman, who served as President and CEO and a board member since 2022, agreed by mutual consent to end his employment effective 14 December 2025. Iain Ross, the company chairman, will lead on an interim basis with immediate effect. James Ede Golightly, a former non-executive director, was re-appointed to the board. The company said it is in robust health both financially and operationally, and an additional US-based board appointment is anticipated in due course.
Silence Therapeutics (Nasdaq: SLN) said management will take part in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 8:00 a.m. ET (1:00 p.m. GMT). The event will be available via a live webcast and an archived replay will be posted afterward in the Investors section of the company website.
Silence Therapeutics (Nasdaq: SLN) reported Q3 2025 results and business updates on November 6, 2025. Key highlights include completion of SANRECO Phase 2 enrollment for divesiran in polycythemia vera (48 phlebotomy-dependent patients) and anticipation of topline results in 3Q 2026. The company reported $102.2 million in cash, cash equivalents and short-term investments as of September 30, 2025, which management expects will fund operations into 2028. Q3 operating figures: R&D $20.5M, G&A $5.8M (down $1.9M YoY), and net loss $21.0M (improved from $35.5M a year earlier).
Silence Therapeutics (Nasdaq: SLN) completed enrollment in the SANRECO Phase 2 study of divesiran, a first-in-class siRNA targeting TMPRSS6 for polycythemia vera (PV).
The global, randomized, double-blind, placebo-controlled study enrolled 48 phlebotomy-dependent PV patients. The primary endpoint is the proportion maintaining hematocrit <45% without phlebotomies between weeks 18 and 36. Secondary endpoints include safety, pharmacokinetics, and quality of life. Topline results are anticipated in 3Q 2026. The Phase 2 design incorporates a 12-week dosing interval informed by Phase 1 data showing durable HCT control with infrequent dosing.
Silence Therapeutics (NASDAQ:SLN), a clinical-stage biotechnology company focused on developing siRNA therapies, has announced its participation in two upcoming investor conferences in September 2025.
Management will present at the Morgan Stanley Global Healthcare Conference on September 9 at 5:35 p.m. ET and the H.C. Wainwright Global Investment Conference on September 10 at 12:00 p.m. ET. Both presentations will be available via webcast through the company's investor relations website.
Silence Therapeutics (NASDAQ:SLN) reported Q2 2025 financial results and clinical progress. The company presented encouraging SANRECO Phase 1 data for divesiran in Polycythemia Vera (PV) at EHA 2025, demonstrating durable hematocrit control and elimination of phlebotomy needs. The Phase 2 SANRECO trial has surpassed 50% enrollment and remains on track for completion by year-end 2025.
Financial highlights include $114.2 million in cash and investments, providing runway into 2028. Q2 2025 saw R&D expenses of $17.6 million (up from $13.8M in Q2 2024) and G&A expenses of $5.1 million (down from $7.0M). Net loss widened to $27.4 million compared to $19.8M in Q2 2024.
The company completed Phase 3 readiness activities for zerlasiran in cardiovascular disease and is pursuing partnership discussions. Silence has paused the Phase 1 study of SLN548 to prioritize promising extra-hepatic cell targeting research.
Summary not available.
Silence Therapeutics (NASDAQ: SLN), a clinical-stage company developing siRNA therapies, has appointed Tim McInerney to its Board of Directors. McInerney brings over 30 years of pharmaceutical and biotechnology experience, including significant roles in early-stage financings of companies like Cougar Biotech and Kite Pharma. He previously served as chairman of Insite Vision and led the Special Committee in Emisphere Technologies' $1.8 billion sale to Novo Nordisk.
The company also announced that James Ede-Golightly will retire from the Board at the June 2025 AGM after serving since 2019. Ede-Golightly played a crucial role in Silence's evolution, including its delisting from the London Stock Exchange and transition to becoming a Nasdaq-listed U.S. domestic issuer.
Silence Therapeutics (Nasdaq: SLN), a global clinical-stage company specializing in siRNA therapies, has announced its upcoming participation in the Leerink Partners Global Healthcare Conference. The company's management will deliver a corporate overview presentation on Wednesday, March 12th at 1:00 p.m. ET.
Interested parties can access the live webcast through the Investors section of Silence's website at www.silence-therapeutics.com. A recorded version of the presentation will be made available for later viewing after the conference concludes.
FAQ
What is the current stock price of Silence Therapeutics Plc (SLN)?
What is the market cap of Silence Therapeutics Plc (SLN)?
